These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9163660)

  • 21. Uncertainty in the diagnosis of cystic fibrosis: possible role of in vivo nasal potential difference measurements.
    Wilson DC; Ellis L; Zielenski J; Corey M; Ip WF; Tsui LC; Tullis E; Knowles MR; Durie PR
    J Pediatr; 1998 Apr; 132(4):596-9. PubMed ID: 9580755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nasal potential difference in congenital bilateral absence of the vas deferens.
    Pradal U; Castellani C; Delmarco A; Mastella G
    Am J Respir Crit Care Med; 1998 Sep; 158(3):896-901. PubMed ID: 9731023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data.
    Derichs N; Sanz J; Von Kanel T; Stolpe C; Zapf A; Tümmler B; Gallati S; Ballmann M
    Thorax; 2010 Jul; 65(7):594-9. PubMed ID: 20627915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests.
    Augarten A; Berman H; Aviram M; Diver-Habber A; Akons H; Ben Tur L; Blau H; Kerem E; Rivlin J; Katznelson D; Szeinberg A; Kerem BS; Theodor L; Paret G; Yahav Y
    Clin Exp Med; 2003 Sep; 3(2):119-23. PubMed ID: 14598187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical spectrum in homozygotes and compound heterozygotes inheriting cystic fibrosis mutation 3849 + 10kbC > T: significance for geneticists.
    Gilbert F; Li Z; Arzimanoglou II; Bialer M; Denning C; Gorvoy J; Honorof J; Ores C; Quittell L; Arzimanoglou I
    Am J Med Genet; 1995 Sep; 58(4):356-9. PubMed ID: 8533846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CFTR genotypes in patients with normal or borderline sweat chloride levels.
    Feldmann D; Couderc R; Audrezet MP; Ferec C; Bienvenu T; Desgeorges M; Claustres M; Mittre H; Blayau M; Bozon D; Malinge MC; Monnier N; Bonnefont JP; Iron A; Bieth E; Dumur V; Clavel C; Cazeneuve C; Girodon E
    Hum Mutat; 2003 Oct; 22(4):340. PubMed ID: 12955726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.
    Rosenstein BJ; Cutting GR
    J Pediatr; 1998 Apr; 132(4):589-95. PubMed ID: 9580754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Borderline sweat test: Utility and limits of genetic analysis for the diagnosis of cystic fibrosis.
    Seia M; Costantino L; Paracchini V; Porcaro L; Capasso P; Coviello D; Corbetta C; Torresani E; Magazzù D; Consalvo V; Monti A; Costantini D; Colombo C
    Clin Biochem; 2009 May; 42(7-8):611-6. PubMed ID: 19318035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular diagnosis of cystic fibrosis in Indian patients--a preliminary report.
    Ashavaid TF; Dherai AJ; Kondkar AA; Raghavan R; Udani SV; Udwadia ZF; Desai D
    J Assoc Physicians India; 2003 Apr; 51():345-8. PubMed ID: 12723646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis.
    Ahrens RC; Standaert TA; Launspach J; Han SH; Teresi ME; Aitken ML; Kelley TJ; Hilliard KA; Milgram LJ; Konstan MW; Weatherly MR; McCarty NA
    Pediatr Pulmonol; 2002 Feb; 33(2):142-50. PubMed ID: 11802252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correlation of results of immunocytochemical, electrophysiologic, and molecular studies in patients with cystic fibrosis].
    Glazkov PB; Ivashchenko TE; Mitkina EN; Gembitskaia TE; Orlov AV; Chermenskii AG; Baranov VS
    Genetika; 2000 Sep; 36(9):1274-8. PubMed ID: 11042815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The significance of sweat Cl/Na ratio in patients with borderline sweat test.
    Augarten A; Hacham S; Kerem E; Sheva Kerem B; Szeinberg A; Laufer J; Doolman R; Altshuler R; Blau H; Bentur L
    Pediatr Pulmonol; 1995 Dec; 20(6):369-71. PubMed ID: 8649916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nasal potential difference: a clinical diagnostic test for cystic fibrosis.
    Alton EW; Currie D; Logan-Sinclair R; Warner JO; Hodson ME; Geddes DM
    Eur Respir J; 1990 Sep; 3(8):922-6. PubMed ID: 2292287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Borderline sweat test: criteria for cystic fibrosis diagnosis.
    Canciani M; Forno S; Mastella G
    Scand J Gastroenterol Suppl; 1988; 143():19-27. PubMed ID: 3164505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-classic cystic fibrosis associated with D1152H CFTR mutation.
    Burgel PR; Fajac I; Hubert D; Grenet D; Stremler N; Roussey M; Siret D; Languepin J; Mely L; Fanton A; Labbé A; Domblides P; Vic P; Dagorne M; Reynaud-Gaubert M; Counil F; Varaigne F; Bienvenu T; Bellis G; Dusser D
    Clin Genet; 2010 Apr; 77(4):355-64. PubMed ID: 19843100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis.
    Clancy JP; Bebök Z; Ruiz F; King C; Jones J; Walker L; Greer H; Hong J; Wing L; Macaluso M; Lyrene R; Sorscher EJ; Bedwell DM
    Am J Respir Crit Care Med; 2001 Jun; 163(7):1683-92. PubMed ID: 11401894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A semi-blinded study comparing 2 methods of measuring nasal potential difference: Subcutaneous needle versus dermal abrasion.
    De Wachter E; De Schutter I; Meulemans A; Buyl R; Malfroot A
    J Cyst Fibros; 2016 Jan; 15(1):60-6. PubMed ID: 26190830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Nasal transepithelial difference of potential in mucoviscidosis. Clinical application of the measurement].
    Maherzi A; Ategbo S; Pharaon I; Munck A; Cezard JP; Foucaud P; Navarro J
    Presse Med; 1995 Mar; 24(9):437-40. PubMed ID: 7746816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased nasal potential difference and amiloride sensitivity in neonates with cystic fibrosis.
    Gowen CW; Lawson EE; Gingras-Leatherman J; Gatzy JT; Boucher RC; Knowles MR
    J Pediatr; 1986 Apr; 108(4):517-21. PubMed ID: 3958823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.